Detalhe da pesquisa
1.
GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.
PLoS One
; 12(3): e0174038, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28301611
2.
GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.
Clin Cancer Res
; 22(13): 3238-48, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27252412